Apparatus and method for lung analysis

• US 20060100666A1
• Filed: 04/21/2005
• Published: 05/11/2006
• Est. Priority Date: 04/20/2000
• Status: Abandoned Application

• Current Assignee: Respiri (Israel) Ltd.
• Original Assignee: PulmoSonix Pty., Ltd. (Spenda Ltd.)
• Inventors: Ramsden, Clive Andrew, Berger, Philip John, Wilkinson, Malcolm Howard
• Application Number:
  US11/111,689
• Publication Number:
  US 20060100666A1
• Time in Patent Office: Days
• US Class Current: 607/1
• CPC Class Codes: A61B 2562/0204 Acoustic sensors
• CPC Class Codes: A61B 2562/046 in a matrix array
• CPC Class Codes: A61B 5/08 Detecting, measuring or recording devices for evaluating the respiratory organs A61B5/0205 takes precedence
• CPC Class Codes: A61B 5/085 Measuring impedance of respiratory organs or lung elasticity
• CPC Class Codes: A61B 5/7257 using Fourier transforms
• CPC Class Codes: A61B 8/08 Detecting organic movements or changes, e.g. tumours, cysts, swellings A61B8/02 - A61B8/06 take precedence

Abstract

An apparatus and method of detecting COPD and in particular, emphysema utilizes a change in acoustic transmission characteristics of a lung due to e.g. the appearance of fenestrae (perforations) in the alveoli of the lung. The use of acoustic signals may provide good sensitivity to the existence of alveolar fenestrae, even for microscopic emphysema, and the appearance and increase in fenestrae may be determined by monitoring acoustic transmission characteristics such as, for example, an increase in acoustic signal velocity and velocity dispersion, and/or a change in attenuation. A transmitter may be located in e.g. the supra-clavicular space and receivers may be mounted on the chest. Measurements may be correlated between pairs of receivers to determine acoustic transmission profiles.

Claims

1. A method for determining the presence of Chronic Obstructive Pulmonary Disease (COPD) in a lung, the method including the steps of:

applying an acoustic signal to the lung;

detecting the signal after it has passed through at least part of the lung; and

determining an acoustic transmission characteristic indicative of the microstructure of the at least part of the lung;

wherein COPD is determined to be present when the acoustic transmission characteristic indicates the existence of a feature of COPD.

2. The method of claim 1, wherein the acoustic signal is in the frequency range of about 20 Hz to about 25 KHz.

3. The method of claim 1, wherein the acoustic signal is in the frequency range of about 70 Hz to about 5 KHz.

4. The method of claim 1, wherein the acoustic signal frequency is less than 1 KHz.

5. The method of claim 1, further including the step of determining the velocity of the detected signal.

6. The method of claim 5, wherein the signal velocity at a particular signal frequency is used to determine COPD.

7. The method of claim 5 wherein velocity dispersion over a range of acoustic frequencies is used to determine COPD.

8. The method of claim 5 wherein a change in velocity is used to determine COPD.

9. The method of claim 1, further including the step of determining attenuation of the detected acoustic signal.

10. The method of claim 9, wherein the signal attenuation at a particular signal frequency is used to determine COPD.

11. The method of claim 10, wherein the frequency dependence of attenuation over a range of acoustic frequencies is used to determine COPD.

12. The method of claim 1, wherein two or more transmission characteristics selected from the group including but not limited to velocity, velocity dispersion, attenuation, attenuation dispersion and acoustic signal power density and dispersion are used to determine COPD or progression thereof.

13. The method of claim 1, wherein the acoustic signal is applied trans-thoracically.

14. The method of claim 1, wherein the acoustic signal is applied in the region of the supra-clavicular space.

15. The method of claim 1, wherein the acoustic signal is detected at two or more locations on the dorsal spine.

16. The method of claim 15, wherein the acoustic transmission characteristic is determined for the lung region between the two detection locations.

17. The method of claim 15, further including the step of cross-correlating the detected signals.

18. The method according to claim 17 further including the step of applying a Fourier transform to the detected signals.

19. The method of claim 1, wherein the acoustic signal is selected from the group of signals including but not limited to:

one or more pure tones applied simultaneously, one or more pure tones applied one after the other, and pseudorandom noise.

20. The method of claim 1, wherein the acoustic transmission characteristic of the lung is determined at functional residual capacity of the lung.

21. The method of claim 1 used to determine a likelihood of an asymptomatic subject developing COPD.

22. The method of claim 1, used to stage progression of COPD in a subject as early, mid or advanced.

23. The method of claim 1 used to determine the existence of COPD in the form of emphysema, wherein an acoustic transmission characteristic indicative of the existence of fenestrae in the at least part of the lung indicates the presence of emphysema.

24. The method of claim 23 used to determine a likelihood of an asymptomatic subject developing emphysema.

25. The method of claim 23 used to stage progression of emphysema in a subject as early, mid or advanced.

26. The method of claim 23 wherein an increase in velocity dispersion is indicative of emphysema.

27. A method for screening participants for an emphysema drug trial according to the method of claim 23, wherein participants determined to have emphysema are considered suitable for the trial.

28. A method, including the steps of claim 23, for determining whether a COPD sufferer is suitable for treatment with a drug for treating emphysema, wherein a COPD sufferer determined to have emphysema is considered suitable.

29. Apparatus for determining the presence of Chronic Obstructive Pulmonary Disease (COPD) in a lung, the apparatus including:

a transmitter for transmitting an acoustic signal into a lung;

one or more receivers for detecting the acoustic signal after it has passed through at least part of the lung; and

a controller/processor for determining an acoustic transmission characteristic indicative of the microstructure of the at least part of the lung and for determining whether the transmission characteristic indicates the presence of a feature of COPD.

30. Apparatus according to claim 29 wherein the one or more receivers are located on the dorsal spine.

31. Apparatus according to claim 29 wherein there are 2 or more receivers located on the torso below the armpit.

32. Apparatus according to claim 30 wherein the receivers are provided in pairs arranged along the dorsal spine.

33. Apparatus according to claim 30 wherein a plurality of receivers are arranged in an array around the dorsal spine.

34. Apparatus according to claim 31 further including a sheath wearable by a subject, the sheath being configured to retain the one or more receivers in position during use of the apparatus.

35. Apparatus according to claim 34 wherein the one or more receivers include hydrophones retained within a fluid-filled cavity of the sheath.

36. Apparatus according to claim 29 further including means to determine a distance between (a) the transmitter and one or more receivers;

and/or (b) two receivers.

37. Apparatus according to claim 29 further including a display device for displaying information relating to one or more factors selected from the group including but not limited to the following:

(a) a likelihood of developing COPD;

(b) a likelihood of developing COPD in the form of emphysema;

(c) a presence of COPD;

(d) a presence of COPD in the form of emphysema;

(e) a stage of COPD;

(f) a stage of COPD in the form of emphysema;

(g) suitability of a subject for participating in an emphysema drug trial;

(h) suitability of a subject for treatment with an emphysema drug; and

(i) a map of the existence of COPD in a subject'"'"'s lung.

38. Apparatus according to claim 29, wherein the transmitter transmits the acoustic signal with a frequency range of about 20 Hz to about 25 KHz.

39. Apparatus according to claim 29, wherein the transmitter transmits the acoustic signal with a frequency range of about 70 Hz to about 5 KHz.

40. Apparatus according to claim 29 wherein the transmitter transmits the acoustic signal with a frequency of less than 5 KHz.

41. Apparatus according to claim 29 wherein the controller/processor is configured to use one or more of the following characteristics to determine presence of COPD in the lung:

(a) velocity of the detected signal;

(b) detected signal velocity at a particular signal frequency;

(c) detected velocity dispersion;

(d) changes in velocity and/or velocity dispersion over time;

(e) acoustic signal attenuation;

(f) acoustic signal attenuation at a particular frequency;

(g) frequency dependence of acoustic signal attenuation;

(h) changes in frequency dependence of acoustic signal attenuation over time;

(i) power distribution over the frequency spectrum of the acoustic signal; and

(j) changes in power distribution over the frequency spectrum of the acoustic signal measured over time.

42. Apparatus according to claim 29 wherein the controller/processor is configured to determine acoustic transmission characteristics for a region of lung located between two receivers.

43. Apparatus according to claim 29 wherein the transmitter transmits an acoustic signal selected from the group including but not limited to:

one or more pure tones applied simultaneously, one or more pure tones applied one after the other, and pseudorandom noise.

44. A method for determining chronic obstructive pulmonary disease (COPD), including the steps of:

applying an acoustic signal to the lung, measuring the signal after it has passed through the lung, determining an acoustic transmission characteristic of the lung, and determining the presence of chronic obstructive pulmonary disease by determining whether the acoustic transmission characteristic indicates the existence of COPD features, e.g. indicate fenestrae in the alveoli.

45. A method of determining emphysema based on an acoustic transmission characteristic of the lung which assumes a lung structure that has a degree of open-cell structure.

46. A method of determining emphysema based on an acoustic transmission characteristic of the lung, including the step of modeling the lung to have a degree of open-cell structure, and determining an acoustic transmission characteristic associated with such a structure.

47. A method for determining the presence of emphysema in a lung, the method including the steps of:

applying an acoustic signal to the lung, detecting the signal after it has passed through at least part of the lung, determining an acoustic transmission characteristic of the lung, and determining the presence of emphysema by determining whether the acoustic transmission characteristic indicates the existence of fenestrae in the alveoli.

48. A method of determining characteristics of biological tissue in situ, including:

introducing a sound to the tissue at first position;

detecting the sound at another position spaced from the first position after it has traveled through the tissue;

calculating the velocity and attenuation of sound that has traveled through the tissue from the first position to another position; and

correlating the velocity and attenuation of the detected sound to characteristics of the biological tissue.